1.C DR, PN M. 2019 Novel Coronavirus-Important Information for Clinicians. JAMA, 2020.
2.D W, N W, KS C, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY), 2020,367(6483):1260–1263.
3.Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses—drug discovery and therapeutic options. Nature Reviews Drug Discovery, 2016.
4.Fu X, Lin L, Tan X. Clinical study on 37 case of COVID–19 treated with integrated traditional Chinese and Western Medicine. Traditional Chinese Drug Research and Clinical Pharmacology, 2020.
5.Fu X, Lin L, Tan X. Clinical Study on Treatment of Cases of COVID–19 with Toujie Quwen Granules. Chinese Journal of Experimental Traditional Medical Formulae, 2020.
6.EJ S, JM K, SH K, et al. Restoring Effects of Natural Anti-Oxidant Quercetin on Cellular Senescent Human Dermal Fibroblasts. The American journal of Chinese medicine, 2018,46(4):853–873.
7.Zhang D, Fang J, Chen J, et al. [An in vitro study of anti-human cytomegalovirus effect of Forsythia suspensa and its main active ingredient quercetin]. Zhongguo Zhong Yao Za Zhi, 2010,35(8):1055–1059.
8.Zhang Z, Guo S, Fu S, et al. Research Progress of Active Ingredients and Pharmacological Action of Honeysuckle. Animal Husbandry and Feed Science, 2014(1):22–24.
9.J.Song HZ, CJ.Guo. Research Progress of Active Ingredients and Pharmacological Action of Honeysuckle. Animal Husbandry and Feed Science:22–24.
10.Hopkins, L A. Network pharmacology: the next paradigm in drug discovery. 2008,4(11):682–690.
11.X L, J W, D Z, et al. Hedyotis diffusaA Network Pharmacology Approach to Uncover the Multiple Mechanisms of Willd. on Colorectal Cancer. Evidence-based complementary and alternative medicine: eCAM, 2018,2018:6517034.
12.Liu J, Pei M, Zheng C, et al. A Systems-Pharmacology Analysis of Herbal Medicines Used in Health Improvement Treatment: Predicting Potential New Drugs and Targets. Evidence-based Complementary and Alternative Medicine, 2013,2013(6):938764.
13.Shannon, P. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 2003,13(11):2498–2504.
14.Z X, L S, Y W, et al. Pathological findings of COVID–19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine, 2020.
15.Yu G. clusterProfiler: an R package for Statistical Analysis and Visualization of Functional Profiles for Genes and Gene Clusters; 2011.
16.Hong XU. Research progress of prostaglandin receptors and related drugs. Journal of China Pharmaceutical University, 2010,41(5):385–394.
17.Mcdougall C, Mckay GA, Fisher M. Drugs for diabetes: Part 5 DPP–4 inhibitors. British Journal of Cardiology, 2011,18(3):130–132.
18.Kitano, H. Systems Biology: A Brief Overview. Science,295(5560):1662–1664.
19.Wang Z, Xu X. scRNA-seq Profiling of Human Testes Reveals the Presence of ACE2 Receptor, a Target for SARS-CoV–2 Infection, in Spermatogonia, Leydig and Sertoli Cells. Preprints 2020.
20.Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV–2.medRxiv 2020.02.17.20023721. 2020.
21.Mao L, Wang M, Chen S, et al. Neurological Manifestations of Hospitalized Patients with COVID–19 in Wuhan, China: a retrospective case series study. 2020.
22.P Z, XL Y, XG W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020,579(7798):270–273.
23.Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life sciences, 2020,63:457–460.
24.Y L, C Z, F H, et al. 2019-novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury. 2020.
25.Y L, Y Y, C Z, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life sciences, 2020,63(3):364–374.